Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
ARGATROBAN IN SODIUM CHLORIDE vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, platelet activation, and clot formation.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Initial dose: 2 mcg/kg/min IV continuous infusion; maintenance: titrate to aPTT 1.5-3 times baseline, not to exceed 10 mcg/kg/min.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Terminal elimination half-life: 39–51 minutes (mean ~45 min) following intravenous infusion. In hepatic impairment, half-life is prolonged up to 3-fold. Short half-life allows rapid offset of anticoagulation if needed.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Primarily hepatic (biliary/fecal); approximately 65% excreted in feces and 22% in urine (unchanged drug minimal). Renal elimination accounts for 16% as unchanged drug. Dosage adjustment required for hepatic impairment; not significantly affected by renal impairment.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte